With rise in Covid-19 cases, India likely to reduce vaccines export: Gavi

With rise in number of Covid-19 cases, India is now likely to make available a smaller number of vaccines to the rest of the world, said the head of Global Alliance for Vaccines and Immunisation

Astrazeneca vaccine
Press Trust of India Washington
3 min read Last Updated : Apr 06 2021 | 6:58 AM IST

India, which is experiencing a sudden rise in number of COVID-19 cases, is now likely to make available a smaller number of vaccines to the rest of the world, the head of the Global Alliance for Vaccines and Immunisation has said.

India is, by volume, the largest supplier of vaccines for the developing world. Because of the new wave of outbreaks in India right now, the Indian government has stepped up their vaccination programmes, and that has meant that they've required more doses, which means that they've made less doses available for the rest of the world, Seth Berkley, CEO of Gavi told CBS News in an interview.

We had expected, in March and April, about 90 million doses, and we suspect we'll get much, much less than that, and that is a problem, he said.

Gavi Alliance is a public-private partnership that works to provide vaccines for developing countries. It provides about 50 per cent of the world's children with vaccines.

But we're in a race because we also see wealthy countries beginning to cover much of their population. Our hope is that they will begin to make their vaccines available to the rest of the world, including ones that they may not use. For example, the US not only has Moderna, Pfizer, and J&J, but they also have vaccines from Novavax and, of course, from AstraZeneca, Berkley said.

Those could be made available, and they would make a big difference in terms of the supply for the world, he said.

Berkley said that the big challenge right now is access to vaccines.

"We have gone ahead and placed orders for more than two billion doses, but the majority of those are coming in the second half of the year. And in the first half of the year, because of vaccine nationalism, has meant that there are less doses available. So that's our big challenge now. If we had more doses, we could make those available, Berkley said.

Responding to a question, Berkley said that what it is talking about now is ultimately getting access to the large manufacturing facilities.

I mean the US invested heavily at the beginning, and scaled up manufacturing, and invested again and scaled up. Once the US needs are met, those facilities really could be used to come online for the rest of the world, which could help stop the acute pandemic. Our goal would be by the end of this year to stop the acute pandemic, which is critical for global health security, he said.

Minister of State for External Affairs V Muraleedharan last month said that India has provided over 481 lakh doses of coronavirus vaccines to various countries, out of which 73.5 lakh doses have been supplied as grant assistance, 288.4 lakh on commercial basis and 119.16 lakh doses for COVAX.

India recorded an all-time highof 1,03,558single day new coronavirusinfections, pushingthe nationwide tally to1,25,89,067, according to the Union Health Ministry data on Monday.The death toll increased to1,65,101 with 478 daily new fatalities, it said.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusCoronavirus VaccineCoronavirus Tests

First Published: Apr 06 2021 | 6:54 AM IST

Next Story